Egyptian Journal of Chemistry

http://ejchem.journals.ekb.eg/

Clinical Applications of Laboratory Chemistry in Early Detection of Metabolic and Endocrine Disorders

Mohammad Raja Aljehani[1*], Wejdan Mohammed Terkustani[1], Nouf Oqla Alahmadi[1], Manal Hamad Abdulrahim Alamri[1], Nuha Abdulfttah Abulula[1], Khulud Ahmed Alqarni[2], Shorooq Eid Ayedh Albishi[2], Ghufran Osama Sager[1], Bayan Mansour Basaid[1]

[1]*National Guard Prince Mohammad Bin Abdulaziz Hospital, Laboratory Technician, Ministry of health, Saudi Arabia*
[2]*National Guard Health Affairs in Jeddah, Laboratory Technician, Ministry of health, Saudi Arabia*

Abstract

Background: Laboratory chemistry plays a critical role in identifying metabolic and endocrine disorders before clinical symptoms emerge. Early detection improves outcomes by enabling timely interventions and informed treatment plans.
Aim: This study explores how laboratory chemistry contributes to the early identification, monitoring, and management of metabolic and endocrine diseases using both routine and specialized diagnostic tests.
Methods: A narrative review was conducted using sources from peer-reviewed journals, laboratory medicine guidelines, and public health data. The review examined the role of standard biomarkers, hormone quantification, dynamic tests, and advanced biochemical profiling.
Results: Routine tests such as glucose, ketones, ammonia, and liver/renal panels help detect inborn errors of metabolism, organ dysfunction, and diabetes. Hormonal measurements of TSH, free T4, cortisol, insulin, and HbA1c support early diagnosis of thyroid disorders, adrenal syndromes, and diabetes. Dynamic testing protocols—like glucose tolerance and ACTH stimulation tests—further enhance diagnostic precision. Laboratory chemistry also facilitates risk assessment, treatment monitoring, and disease progression tracking.
Conclusion: Laboratory chemistry is essential in the early detection and clinical management of metabolic and endocrine disorders. Its ability to identify biochemical changes before the onset of disease symptoms improves prognosis and allows for targeted interventions. Continuous technological advances, such as automation and biomarker expansion, will strengthen its role in future healthcare strategies.

Keywords: Laboratory chemistry, metabolic disorders, endocrine disorders, hormone testing, early detection, biomarkers, disease monitoring, clinical diagnostics, healthcare management.

1. Introduction

Laboratory chemistry, often referred to as clinical chemistry or chemical pathology, plays a foundational role in modern medical diagnostics by facilitating the early identification and continuous monitoring of a wide range of metabolic and endocrine disorders. Through the analysis of biological specimens such as blood, urine, and other body fluids, this field enables healthcare professionals to detect pathological changes in the body's biochemical environment even before clinical symptoms become evident. This early detection capability is especially important in conditions that progress silently or have nonspecific early manifestations, such as diabetes mellitus, thyroid dysfunctions, and electrolyte imbalances. By providing quantitative assessments of key analytes—such as glucose, electrolytes, hormones, enzymes, and metabolic waste products—laboratory chemistry allows for a deeper understanding of the underlying physiological disturbances associated with various disorders. This data is critical not only for confirming a diagnosis but also for assessing the severity of the disease, establishing a baseline for future comparison, and selecting appropriate treatment strategies. For example, elevated fasting glucose or glycated hemoglobin (HbA1c) levels can signal the presence of diabetes at a stage where lifestyle modification or early pharmacologic intervention can prevent complications. Similarly, abnormalities in thyroid hormone levels can be detected before clinical signs of hypo- or hyperthyroidism emerge, allowing for prompt therapeutic response. Moreover, the ongoing use of clinical chemistry in monitoring disease progression and therapeutic effectiveness ensures that patients receive timely adjustments to their management plans. This continuous feedback loop between biochemical data and clinical decision-making contributes to improved patient outcomes, reduced healthcare costs, and more efficient use of medical resources. As healthcare increasingly emphasizes precision and prevention, the role of laboratory chemistry remains central to achieving these goals through reliable, evidence-based testing and interpretation (Ping, M; 2023; Clinical chemistry, n.d.) (1).

Core Laboratory Chemistry Techniques

Laboratory chemistry relies on a range of well-established analytical methods that form the foundation of diagnostic testing. Among the most widely used is spectrophotometry, a technique that quantifies the concentration of substances in

_____

biological samples by measuring the amount of light absorbed at specific wavelengths. This method operates on the principle that different compounds absorb light differently depending on their molecular structure and the wavelength used. Spectrophotometry is routinely applied in the analysis of both blood and urine samples. For example, it is used to determine concentrations of glucose, creatinine, urea, and bilirubin—analytes that are essential in assessing kidney and liver function, as well as metabolic status. The method's simplicity, speed, and ability to be automated make it suitable for high-throughput clinical laboratories, where large volumes of samples must be processed with consistent accuracy. Immunoassays represent another critical class of laboratory chemistry techniques, particularly important in the detection and quantification of specific proteins, hormones, and therapeutic drugs. These assays are based on the highly specific interaction between antigens and antibodies, allowing for the sensitive identification of target molecules even at very low concentrations. Immunoassays are extensively used in hormone testing, such as for thyroid hormones (T3, T4, TSH), reproductive hormones (FSH, LH, estradiol, progesterone), and markers for cancer and cardiac disease. The technique is also fundamental in therapeutic drug monitoring and in assessing exposure to toxins or infectious agents. The versatility of immunoassays has led to their widespread adoption in automated analyzers, enhancing their utility in both routine and specialized laboratory settings. Their specificity and adaptability allow laboratories to expand testing menus while maintaining high diagnostic accuracy (McGraw Hill, 2022) (2).

For more complex analytical needs, especially those involving structurally similar or low-concentration compounds, chromatography combined with mass spectrometry provides a powerful solution. Chromatography, including liquid and gas chromatography, functions by separating compounds within a mixture based on their physical or chemical properties, such as polarity or molecular weight. Once separated, the components are introduced into a mass spectrometer, which identifies and quantifies the compounds based on their mass-to-charge ratios. This tandem method is particularly valuable in the investigation of metabolic disorders, drug screening, and toxicology. It is capable of detecting trace amounts of biomarkers or contaminants that may not be measurable by more conventional techniques. Chromatography and mass spectrometry are indispensable in confirming diagnoses that require a high degree of specificity and sensitivity, such as inborn errors of metabolism or complex endocrine abnormalities. Together, these core techniques—spectrophotometry, immunoassays, chromatography, and mass spectrometry—form the analytical backbone of clinical chemistry. They enable laboratories to deliver accurate and clinically meaningful results across a broad spectrum of diagnostic categories. Each method offers unique advantages in terms of precision, sensitivity, speed, and applicability, allowing laboratories to tailor their testing strategies to the clinical needs of individual patients. As diagnostic science continues to evolve, these methodologies remain central to innovation, offering the reliability and flexibility required for modern, patient-centered healthcare (Jellum, 1986) (3).

Laboratory Chemistry in Metabolic Disorder Detection

Metabolic disorders frequently manifest through vague or non-specific clinical symptoms, making their diagnosis challenging without laboratory support. Clinical chemistry plays a fundamental role in addressing this diagnostic uncertainty by offering targeted biochemical tests that support early identification and intervention. One of the core tools in this context is the routine screening panel, commonly known as the basic metabolic panel (BMP). This set of tests evaluates critical components such as electrolytes, blood glucose, renal markers like creatinine and urea, and liver enzymes. These parameters provide insights into major organ functions and overall metabolic balance, which are crucial for detecting conditions such as diabetes, renal insufficiency, hepatic impairment, and even inborn errors of metabolism (IEM) in their early stages. The rapid availability and standardized nature of these tests make them central to both outpatient and inpatient assessments. Beyond routine screening, specialized analysis of metabolites significantly enhances the ability to diagnose complex and rare metabolic diseases. Specific tests target abnormal levels of organic acids, amino acids, ketones, and other small molecules in blood and urine. These advanced assays support the diagnosis of over 100 inherited and acquired metabolic disorders. For example, elevated levels of specific amino acids can indicate phenylketonuria or maple syrup urine disease, while abnormal organic acid profiles may signal methylmalonic acidemia or propionic acidemia. These disorders often require timely identification to avoid irreversible complications such as neurological damage or metabolic crises. By quantifying these specific biochemical abnormalities, laboratory chemistry allows for early recognition and disease stratification that guides further genetic or enzymatic testing (Stanford Health Care; n.d.) (4).

One of the most impactful applications of clinical chemistry in this domain is newborn screening. National and regional programs worldwide have implemented widespread biochemical testing shortly after birth to detect metabolic disorders that would otherwise remain hidden until symptoms become severe. Using heel-prick blood samples, laboratories perform tandem mass spectrometry and other targeted assays to screen for conditions like congenital hypothyroidism, galactosemia, and medium-chain acyl-CoA dehydrogenase deficiency (MCADD). These tests enable prompt initiation of dietary modifications or pharmacological treatments that prevent morbidity and mortality. Without such early detection, many of these diseases would lead to irreversible damage within the first few months of life. In clinical practice, the integration of routine screening, specialized metabolite analysis, and newborn testing ensures a comprehensive approach to metabolic disorder detection. This triad enables clinicians to identify both common and rare disorders, monitor disease progression, and implement tailored interventions that improve prognosis. As analytical technologies advance and more biomarkers become clinically validated, the scope and accuracy of laboratory chemistry in managing metabolic diseases will continue to expand, reinforcing its role as a cornerstone of diagnostic medicine (Guerrero, 2018) (5).

Common Early Indicators of Metabolic Disorders

Clinical chemistry offers vital tools for detecting early metabolic disturbances through specific biomarkers measurable in blood or urine. These biochemical indicators provide essential clues to underlying pathologies, often before clinical symptoms fully manifest. Early identification enables timely interventions that can significantly alter disease

_____

progression, particularly in pediatric and neonatal populations where many metabolic conditions are first encountered. Blood glucose testing is one of the most commonly used screening methods. Abnormal glucose levels, especially persistent hyperglycemia, often indicate diabetes mellitus. In pediatric populations, hypoglycemia or inconsistent glucose levels can point to glycogen storage disorders (GSDs), which impair the body's ability to store or mobilize glucose efficiently. For instance, GSD type I (von Gierke disease) is characterized by severe fasting hypoglycemia and elevated lactate, uric acid, and lipids. Routine measurement of glucose levels is essential for monitoring disease control in known diabetic patients and for initial evaluation in undiagnosed individuals showing symptoms such as fatigue, irritability, or altered consciousness (Stanford Health Care; n.d.) (4).

Another critical early biochemical indicator is the presence of ketones in blood or urine. Elevated ketone levels are typical during prolonged fasting or carbohydrate restriction, but when they occur inappropriately or excessively, they may indicate defects in fatty acid oxidation. Disorders like medium-chain acyl-CoA dehydrogenase deficiency (MCADD) prevent the normal breakdown of fatty acids for energy, leading to hypoketotic hypoglycemia during metabolic stress. Routine detection of blood or urinary ketones in acutely ill or hypoglycemic patients aids in rapid identification of such inborn errors and prevents progression to metabolic crises. Lactate levels are equally significant in the evaluation of metabolic and mitochondrial conditions. Elevated blood lactate may suggest impaired oxidative phosphorylation, leading to increased reliance on anaerobic glycolysis. Conditions such as mitochondrial myopathies and pyruvate dehydrogenase complex deficiency typically exhibit chronic or episodic lactic acidosis. Measuring lactate levels helps clinicians assess tissue oxygenation and energy metabolism, which is essential when evaluating a patient presenting with unexplained neurological symptoms or developmental delays (Guerrero, 2018) (5).


Figure 1: Key Characteristics of Endocrine-Disrupting Chemicals

Ammonia testing is another important component of metabolic screening, especially in the context of suspected urea cycle disorders (UCDs). Elevated ammonia levels result from the body's inability to detoxify nitrogen waste, leading to hyperammonemia. This condition often presents with nonspecific symptoms such as vomiting, lethargy, or behavioral changes but can rapidly progress to encephalopathy if not identified and treated. Prompt laboratory measurement of plasma ammonia allows for early diagnosis and initiation of protein-restricted diets or ammonia-scavenging drugs to avoid irreversible neurological damage. Liver and renal function panels also contribute significantly to early detection of metabolic diseases. Elevated liver enzymes (AST, ALT), bilirubin, or abnormal coagulation profiles can indicate hepatic involvement in conditions such as galactosemia, tyrosinemia, or Wilson disease. Similarly, abnormal creatinine or urea levels suggest renal impairment, which may be due to metabolic causes like cystinosis or methylmalonic acidemia. In many cases, combined liver and renal dysfunction may be the first sign of systemic metabolic disturbances, especially in newborns or infants presenting with failure to thrive or recurrent vomiting. Together, these early laboratory indicators form the foundation of diagnostic algorithms for

metabolic diseases. Their interpretation, in conjunction with clinical findings, guides further testing such as enzyme assays, genetic studies, or metabolic panels. Advances in laboratory technology and increased awareness among clinicians have greatly improved early detection rates, allowing for timely interventions that prevent long-term complications and improve survival outcomes. Clinical chemistry remains an indispensable part of the diagnostic process, offering rapid, quantifiable insights into complex metabolic disorders across all age groups (Guerrero, 2018) (5).

Laboratory Chemistry in Endocrine Disorder Detection

Laboratory chemistry plays a foundational role in the early identification, diagnosis, and management of endocrine disorders. Many endocrine dysfunctions present subtly or remain asymptomatic in their early stages. Timely laboratory testing facilitates detection before overt clinical symptoms arise, enabling earlier interventions and improved outcomes. Hormone quantification is central to endocrine evaluation. Measuring hormone concentrations in serum or plasma allows clinicians to assess the functional state of various glands, including the thyroid, adrenal, pituitary, pancreas, and gonads. Thyroid-stimulating hormone (TSH) and free thyroxine (free T4) are primary markers in assessing thyroid function. Abnormalities in TSH, such as elevated levels with low free T4, suggest hypothyroidism, whereas suppressed TSH with elevated free T4 indicates hyperthyroidism. Subclinical thyroid dysfunctions, detectable only through abnormal hormone levels without symptoms, can progress to overt disease if untreated. Early detection enables timely therapeutic decisions and reduces the risk of complications such as cardiovascular disease or developmental delays in children. The hypothalamic-pituitary-adrenal axis is evaluated through cortisol and adrenocorticotropic hormone (ACTH) measurements. Low cortisol with elevated ACTH indicates primary adrenal insufficiency (Addison's disease), while high cortisol with suppressed ACTH may suggest Cushing's syndrome, often due to exogenous corticosteroid use or adrenal tumors. In cases of suspected central (secondary) adrenal insufficiency, both cortisol and ACTH may be low due to pituitary dysfunction. These disorders often present with non-specific signs such as fatigue, weight changes, or mood disturbances, making hormone analysis essential for differential diagnosis (Deulkar, 2024) (6).

Diabetes mellitus is another endocrine disorder where laboratory chemistry is indispensable. Measurement of fasting blood glucose and glycated hemoglobin (HbA1c) serves as a cornerstone for diagnosis and monitoring. HbA1c reflects average blood glucose over the preceding two to three months, providing a stable and reliable index of long-term glycemic control. Elevated fasting glucose and HbA1c levels above diagnostic thresholds confirm diabetes, while borderline levels may identify individuals with impaired glucose tolerance or prediabetes, offering a window for preventive interventions. Postprandial glucose measurements and oral glucose tolerance tests are also used to assess the body's response to glucose challenges, helping to identify metabolic disturbances in insulin sensitivity or secretion. Gonadal and pituitary hormone evaluation contributes to the diagnosis of reproductive and developmental disorders. In men, abnormal levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone may indicate hypogonadism, while in women, imbalances in LH, FSH, estradiol, and prolactin are associated with menstrual irregularities, infertility, or polycystic ovary syndrome (PCOS). Elevated prolactin (hyperprolactinemia) may signal a pituitary adenoma or be drug-induced. Pituitary hormone panels, including growth hormone and insulin-like growth factor 1 (IGF-1), are useful for diagnosing acromegaly or growth hormone deficiency. These tests are particularly critical in pediatric and adolescent populations, where delayed or accelerated growth may reflect underlying hormonal disorders (Deulkar, 2024) (6).

Biomarker analysis is gaining prominence in endocrine pathology. For diabetes, in addition to HbA1c, insulin and C-peptide levels provide insight into pancreatic beta-cell function and help differentiate between type 1 and type 2 diabetes. For neuroendocrine tumors, biomarkers such as chromogranin A, neuron-specific enolase, and 5-hydroxyindoleacetic acid (5-HIAA) in urine are valuable for early detection and monitoring. These markers often rise before clinical symptoms become evident, offering diagnostic utility for tumors of the adrenal medulla, pancreas, and gastrointestinal tract. Dynamic testing remains a critical component of endocrine evaluation, particularly when basal hormone levels are inconclusive. These tests assess the endocrine system's ability to respond to physiological stimuli. The ACTH stimulation test is used to assess adrenal reserve in suspected Addison's disease. Patients receive synthetic ACTH, and cortisol levels are measured at intervals to evaluate adrenal gland response. A blunted or absent response confirms adrenal insufficiency. Similarly, the oral glucose tolerance test evaluates insulin sensitivity and beta-cell function by monitoring glucose and insulin levels after glucose ingestion. This test is particularly helpful in gestational diabetes or prediabetes screening (Gounden, 2024) (7).

Stimulation and suppression tests are also used in thyroid and pituitary evaluations. The thyrotropin-releasing hormone (TRH) stimulation test can be applied in complex cases of thyroid dysfunction, while dexamethasone suppression testing helps differentiate types of Cushing's syndrome by assessing the feedback inhibition of cortisol secretion. Overall, endocrine disorders are often systemic and multisymptomatic, making laboratory chemistry essential for accurate diagnosis. Through precise quantification of hormones and analysis of biochemical markers, clinicians can identify dysfunction at early stages, monitor progression, and assess response to therapy. The integration of laboratory results with clinical findings ensures individualized treatment plans and better patient outcomes. As laboratory techniques become more sensitive and automated, and as reference ranges evolve with age, sex, and circadian rhythms, the diagnostic power of clinical chemistry in endocrinology continues to expand, supporting personalized and evidence-based care (Gounden, 2024) (7).

Clinical Impact and Advantages of Laboratory Chemistry in Endocrine and Metabolic Disorders

The application of laboratory chemistry has significantly transformed the detection, monitoring, and prevention of endocrine and metabolic disorders. Its clinical impact lies in its ability to generate accurate biochemical data that guides patient care long before physical symptoms appear. This pre-symptomatic detection is critical in reducing long-term complications and optimizing resource utilization in healthcare systems. One of the most important contributions of laboratory chemistry is early

detection of disease before irreversible damage occurs. Many endocrine and metabolic conditions—such as hypothyroidism, diabetes mellitus, and inborn errors of metabolism—initially progress without clear clinical signs. By measuring biochemical markers like blood glucose, thyroid-stimulating hormone (TSH), or specific metabolic byproducts in blood or urine, laboratory testing can identify pathophysiological changes at an early stage. For example, newborn screening programs that test for congenital hypothyroidism or phenylketonuria (PKU) have prevented cognitive disability and severe metabolic crises in thousands of infants worldwide. Similarly, elevated fasting blood glucose or hemoglobin A1c in otherwise asymptomatic individuals often reveals prediabetes or undiagnosed type 2 diabetes. Early recognition allows timely medical or lifestyle interventions, potentially halting disease progression (Gounden, 2024) (7).

Laboratory testing also plays a central role in monitoring disease activity and treatment effectiveness. Chronic diseases such as diabetes, hypothyroidism, and adrenal insufficiency require regular biochemical evaluation to ensure proper control. For instance, in diabetic patients, serial HbA1c assessments help determine whether current therapies maintain target glycemic levels. In hypothyroidism, monitoring TSH and free T4 levels ensures adequate thyroid hormone replacement. These measurements not only validate therapeutic decisions but also allow for timely adjustments when targets are not met or when symptoms persist. Monitoring also extends to patients with more complex conditions, such as Cushing's syndrome or acromegaly, where hormone levels must be repeatedly assessed to gauge surgical outcomes or responses to pharmacologic therapies. Laboratory-based data, therefore, serve as a quantitative feedback mechanism for clinicians to individualize treatment. Another major advantage of laboratory chemistry is its role in risk stratification and preventive healthcare. Through population screening and family-based studies, laboratory biomarkers can identify individuals at elevated risk of developing disease. A classic example is screening relatives of individuals with genetic metabolic disorders such as familial hypercholesterolemia or hereditary hemochromatosis. Biochemical markers like lipid profiles or serum ferritin can identify carriers or at-risk individuals even in the absence of symptoms. Similarly, the identification of impaired fasting glucose or abnormal oral glucose tolerance tests in overweight individuals points to elevated diabetes risk, prompting earlier lifestyle or pharmacological intervention. Risk assessment through laboratory evaluation is not limited to hereditary conditions but is also applicable to environmental and behavioral exposures that influence endocrine health, such as iodine deficiency or prolonged corticosteroid use (Deulkar, 2024) (6).

In addition to direct patient benefits, laboratory chemistry facilitates public health interventions by enabling large-scale surveillance of metabolic and endocrine disorders. For example, trends in population HbA1c levels, TSH distributions, or vitamin D deficiency prevalence offer data for regional health planning and policy development. These indicators also guide resource allocation for preventive programs, drug procurement, or diagnostic infrastructure. Overall, the clinical advantages of laboratory chemistry lie in its objective, reproducible, and scalable nature. Its data-driven insights bridge the gap between molecular dysfunction and clinical disease. By enabling early detection, tracking therapeutic responses, and identifying individuals at risk, laboratory chemistry supports targeted interventions that improve outcomes and reduce the burden on healthcare systems. As technologies evolve and personalized medicine becomes more widespread, the role of laboratory chemistry in predictive, preventive, and precision healthcare will continue to grow (Deulkar, 2024) (6).

Future Trends in Laboratory Chemistry

The future of laboratory chemistry is shaped by rapid advances in molecular biology, automation, and data science. These developments are expanding diagnostic capabilities and enabling earlier, more precise, and more individualized detection of endocrine and metabolic disorders. One major trend is the integration of emerging biomarkers through technologies such as genomics, proteomics, and metabolomics. Unlike traditional biochemical markers, these approaches provide a deeper view into molecular dysfunction. Genomics can identify inherited mutations linked to metabolic syndromes or endocrine tumors, enabling preventive screening in asymptomatic carriers. Proteomics explores protein expression patterns, revealing early changes in hormonal signaling or enzyme activity before symptoms appear. Metabolomics, by analyzing small molecules involved in cellular metabolism, helps identify disease-specific metabolic fingerprints. These new biomarkers expand the clinical reach of laboratory chemistry, allowing detection at a preclinical stage and uncovering rare or complex disorders that traditional assays might miss. Automation is another driving force. Modern clinical laboratories are equipped with high-throughput analyzers capable of processing thousands of samples per day with minimal human input. These systems increase speed and consistency while reducing human error. More importantly, they support broad population screening for diseases such as diabetes, thyroid disorders, or congenital metabolic diseases. With automation, cost and time barriers are reduced, making large-scale preventive testing more practical for healthcare systems ((Deulkar, 2024) (6).

Algorithms and artificial intelligence are now being embedded in laboratory processes to interpret complex datasets and identify abnormal patterns. Predictive models can use laboratory data alongside patient demographics and genetic information to estimate disease risk or suggest a diagnosis. For example, machine learning tools can analyze variations in metabolic panels to flag inborn errors of metabolism or predict insulin resistance trends from serial glucose data. These decision-support tools enhance the clinical value of routine laboratory data by linking patterns to actionable outcomes. Together, these trends signal a transformation in laboratory chemistry from reactive diagnostics to proactive health management. By using molecular insights and smart technology, laboratories are shifting toward precision medicine—where early, individualized, and data-informed interventions are possible. As these tools become more accessible, the scope of laboratory chemistry in metabolic and endocrine care will continue to expand (Gounden, 2024) (7).

Conclusion:

Laboratory chemistry plays a foundational role in detecting metabolic and endocrine disorders at early or even preclinical stages. By evaluating blood, urine, and other body fluids, it enables clinicians to identify subtle biochemical

_____

deviations that precede physical symptoms. This early detection supports timely interventions that can reduce morbidity and improve long-term health outcomes. In metabolic disorders, routine laboratory tests such as blood glucose, serum ketones, lactate, ammonia, liver and kidney function panels provide crucial initial clues. These parameters help detect inborn errors of metabolism, mitochondrial disorders, urea cycle defects, and organ-specific metabolic dysfunctions. Specialized biochemical testing—such as organic acid, amino acid, and acylcarnitine profiling—further enhances the diagnostic capability, particularly in pediatric or neonatal screening programs. Early identification of these disorders allows for dietary, enzymatic, or pharmacological interventions that can prevent serious developmental or systemic complications. For endocrine disorders, laboratory chemistry supports the measurement of hormonal levels across various glands including thyroid, adrenal, pituitary, pancreas, and gonads. Tests for thyroid-stimulating hormone (TSH), free thyroxine (T4), cortisol, adrenocorticotropic hormone (ACTH), insulin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin are essential for detecting dysfunctions like hypothyroidism, Addison's disease, Cushing's syndrome, and diabetes. Biomarkers such as HbA1c for diabetes or chromogranin A for neuroendocrine tumors allow for monitoring and risk stratification. Additionally, dynamic testing protocols such as glucose tolerance tests or ACTH stimulation tests assess the responsiveness of the endocrine system under stress or challenge. Laboratory chemistry not only enables diagnosis but also supports disease monitoring and treatment optimization. Repeated measurements guide therapeutic adjustments, track disease progression, and support long-term follow-up. This continuous feedback loop is critical for managing chronic endocrine or metabolic conditions. As laboratory technologies advance, incorporating high-throughput automation and molecular diagnostics, the ability to detect and manage these disorders is expected to become even more precise and widespread.

References:

1. Ping, M. (2023). *Significance and applications of clinical chemistry in modern medicine* [Perspective]. *Archives of Clinical Pathology, 6*(1). https://doi.org/10.2324-8955/acpy.05.03.100072

2. McGraw Hill (2022). Methods in clinical chemistry and general methods. Laposata M, & McCaffrey P(Eds.), *Clinical Laboratory Methods: Atlas of Commonly Performed Tests*. McGraw Hill, LLC. https://accessmedicine.mhmedical.com/content.aspx?bookid=3128&sectionid=262427596

3. Jellum, E., Kvittingen, E. A., Thoresen, O., Guldal, G., Horn, L., Seip, R., & Stokke, O. (1986). Systematic laboratory diagnosis of human metabolic disorders. *Scandinavian journal of clinical and laboratory investigation. Supplementum*, *184*, 11–20.

4.Stanford Health Care. (n.d.). *Clinical chemistry*. Stanford Anatomic Pathology & Clinical Laboratories. Retrieved July 19, 2025, from https://stanfordlab.com/clinical-pathology/clinical-chemistry.html

5.Guerrero, R. B., Salazar, D., & Tanpaiboon, P. (2018). Laboratory diagnostic approaches in metabolic disorders. *Annals of translational medicine*, *6*(24), 470. https://doi.org/10.21037/atm.2018.11.05

6.Deulkar, P., Singam, A., & Jain, A. (2024). A Comprehensive Review of the Role of Biomarkers in the Early Detection of Endocrine Disorders in Critical Illnesses. *Cureus*, *16*(5), e61409. https://doi.org/10.7759/cureus.61409

7.Gounden, V., & Tanpaiboon, P. (2024). Editorial: New insights: developments in laboratory testing for the diagnosis and monitoring of endocrine related disorders and metabolic disease. *Frontiers in endocrinology*, *15*, 1524950. https://doi.org/10.3389/fendo.2024.1524950

Clinical chemistry. (n.d.). In *Wikipedia*. Retrieved July 19, 2025, from https://en.wikipedia.org/wiki/Clinical_chemistry

_____